Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle
Marc Kennis, March 1, 2022
Cyclopharm
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!
Stay up-to-date on ASX-listed Life Sciences stocks!
Make sure you subscribe to Stocks Down Under today
No credit card needed and the trial expires automatically.
Blog Categories
Recent Posts
BHP wants to buy Anglo American, but what would the potential $60bn deal mean?
In what was meant to be a quiet week on the markets, investors learned yesterday that BHP wants to buy…
Here are 5 ASX resources juniors with projects in unusual locations
ASX resources juniors live and die by many things, but project location is one of them. The majority have projects…
What are nominee shareholders? Have they got anything secret to hide from the rest of the market?
Let’s take a look at who nominee shareholders are. Have you ever seen a substantial shareholder notice lodged with your…